These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23925139)

  • 1. Stability of sotalol hydrochloride in extemporaneously prepared oral suspension formulations.
    Sidhom MB; Rivera N; Almoazen H; Taft DR; Kirschenbaum HL
    Int J Pharm Compd; 2005; 9(5):402-6. PubMed ID: 23925139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide stability in extemporaneously compounded oral suspensions.
    Trissel LA; Zhang Y; Koontz SE
    Int J Pharm Compd; 2006; 10(5):396-9. PubMed ID: 23974320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naratriptan hydrochloride in extemporaneosly compounded oral suspensions.
    Zhang YP; Trissel LA; Fox JL
    Int J Pharm Compd; 2000; 4(1):69-71. PubMed ID: 23985892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of sotalol in two liquid formulations at two temperatures.
    Nahata MC; Morosco RS
    Ann Pharmacother; 2003 Apr; 37(4):506-9. PubMed ID: 12659604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of ciprofloxacin in an extemporaneous oral liquid dosage form.
    Johnson CE; Wong DV; Hoppe HL; Bhatt-Mehta V
    Int J Pharm Compd; 1998; 2(4):314-7. PubMed ID: 23989641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of two concentrations of tiagabine in an extemporaneously compounded suspension.
    Haase MR; Khan MA; Bonilla J
    Int J Pharm Compd; 2003; 7(6):485-9. PubMed ID: 23979810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of an extemporaneous alcohol-free melatonin suspension.
    Johnson CE; Cober MP; Thome T; Rouse E
    Am J Health Syst Pharm; 2011 Mar; 68(5):420-3. PubMed ID: 21330684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of extemporaneously prepared rufinamide oral suspensions.
    Hutchinson DJ; Liou Y; Best R; Zhao F
    Ann Pharmacother; 2010 Mar; 44(3):462-5. PubMed ID: 20150505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of an extemporaneously compounded clonidine hydrochloride oral liquid.
    Levinson ML; Johnson CE
    Am J Hosp Pharm; 1992 Jan; 49(1):122-5. PubMed ID: 1570852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of an extemporaneously prepared alcohol-free phenobarbital suspension.
    Cober MP; Johnson CE
    Am J Health Syst Pharm; 2007 Mar; 64(6):644-6. PubMed ID: 17353574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of extemporaneously prepared cinacalcet oral suspensions.
    Thomson K; Hutchinson DJ; Chablani L
    Am J Health Syst Pharm; 2018 May; 75(9):e236-e240. PubMed ID: 29691267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term stability of atenolol in oral liquid formulations.
    Patel D; Doshi DH; Desai A
    Int J Pharm Compd; 1997; 1(6):437-9. PubMed ID: 23989440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of extemporaneously prepared glycopyrrolate oral suspensions.
    Cober MP; Johnson CE; Sudekum D; Penprase K
    Am J Health Syst Pharm; 2011 May; 68(9):843-5. PubMed ID: 21515869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of extemporaneously prepared moxifloxacin oral suspensions.
    Hutchinson DJ; Johnson CE; Klein KC
    Am J Health Syst Pharm; 2009 Apr; 66(7):665-7. PubMed ID: 19299374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of dolasetron in two oral liquid vehicles.
    Johnson CE; Wagner DS; Bussard WE
    Am J Health Syst Pharm; 2003 Nov; 60(21):2242-4. PubMed ID: 14619116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of extemporaneously prepared oxandrolone oral suspensions.
    Johnson CE; Cober MP; Hawkins KA; Julian JD
    Am J Health Syst Pharm; 2011 Mar; 68(6):519-21. PubMed ID: 21378300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids.
    Allen LV; Erickson MA
    Am J Health Syst Pharm; 1998 Sep; 55(17):1804-9. PubMed ID: 9775343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding.
    Zhao F; Dave VS; Mar MZ; Perri JR
    Int J Pharm Compd; 2018; 22(5):433-439. PubMed ID: 30384342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.
    Li Q; Liu Z; Kolli S; Wetz K; Griffith N; Poi MJ
    Am J Health Syst Pharm; 2016 Sep; 73(17):1331-7. PubMed ID: 27543577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability and uniformity of extemporaneous preparations of voriconazole in two liquid suspension vehicles at two storage temperatures.
    Nguyen KQ; Hawkins MG; Taylor IT; Wiebe VJ; Tell LA
    Am J Vet Res; 2009 Jul; 70(7):908-14. PubMed ID: 19566477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.